Pfizer and BioNTech said Friday that the immune responses against Omicron BA.4/BA.5 subvariants were "substantially higher" in people who got its new bivalent booster compared with people who received ...
BioNTech Omicron BA.4/BA.5 Booster targets the newer Omicron subvariants with an updated mRNA formulation cleared in multiple regions. The BioNTech SE stock (ISIN US09075V1026) benefits from this ...
The companies announced Monday they have submitted an application to provide the updated COVID-19 shot for children ages 5-11. The updated shot gives protection both against the original and omicron ...
Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities ...
Morning Overview on MSN
Pfizer and BioNTech pause US COVID vaccine trial after slow enrollment
Pfizer and BioNTech have paused a large U.S. clinical trial designed to test their updated COVID-19 vaccine in healthy adults aged 50 through 64, citing an inability to recruit enough participants.
The Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) in its updated formulation targets current SARS-CoV-2 variants and remains a key product in Pfizer’s vaccine portfolio. This product is driving the ...
Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results